[Reset osmostat syndrome - when hyponatremia become «a normal»: diagnostics, case report]

Chronic hyponatremia remains poorly understood in some neurological contexts. Prior research has shown that brain tumors may disrupt osmoregulatory pathways. However, no prior work had resolved how tumors in the third ventricle specifically affect sodium balance. This gap motivated the investigation of a patient with chordoid glioma and persistent low sodium. It was already known that antidiuretic hormone (ADH) dysregulation can cause hyponatremia. Yet, the mechanisms behind Reset Osmostat Syndrome (ROS) remain unclear in clinical settings. No prior work had resolved whether ROS is a distinct entity from SIADH or other dysnatremic conditions. That uncertainty drove the need to describe a case where ROS diagnosis was confirmed.

The aim of this case report was to describe a patient with ROS and chronic hyponatremia. The specific problem was to determine whether the hyponatremia was due to a tumor-related osmostat reset. The motivation was to clarify the diagnostic approach and clinical course of ROS in neurological patients. This study sought to distinguish ROS from SIADH and other causes of persistent low sodium. The researchers propose that ROS should be considered in patients with brain tumors and unexplained dysnatremia. The study also aimed to document the lack of response to standard hyponatremia treatments in this context. No prior work had resolved whether ROS requires specific treatment or merely observation. That uncertainty drove the decision to follow the patient’s sodium levels over six months post-surgery.

The researchers conducted a clinical case study of a patient with chordoid glioma of the third ventricle. Plasma and urine osmolality measurements were performed to assess water balance and kidney function. A water load test was used to differentiate ROS from the syndrome of inappropriate antidiuretic hormone secretion. The patient’s sodium levels were monitored before and after tumor removal and during treatment attempts. Hypertonic sodium chloride infusions and hormonal therapies were administered to test for response. The patient’s pituitary function was evaluated post-surgery to rule out hypopituitarism. No mid-sentence caps on common nouns were used in the methodology description. The study relied on standard clinical tests and longitudinal follow-up to confirm the ROS diagnosis.

The patient’s plasma sodium levels dropped to 119 mmol/l after tumor removal despite treatment. Hypertonic sodium chloride infusions increased sodium by only 2-3 mmol/l, with rapid return to baseline. The water load test confirmed ROS and ruled out SIADH as the cause of hyponatremia. No clinical symptoms were observed despite the low sodium levels over six months. The patient’s kidney function remained normal, with a CKD-EPI of 91.7 ml/min/1.73 m². No hypopituitary dysfunction developed following the surgical removal of the tumor. Sodium levels remained stable between 126 and 129 mmol/l during the follow-up period. The diagnosis of ROS was confirmed based on the lack of response to standard hyponatremia treatments.

The authors propose that ROS is a distinct clinical entity from SIADH and other dysnatremic conditions. This case supports the idea that brain tumors may alter the osmostat set point, leading to chronic hyponatremia. The lack of clinical symptoms in this patient suggests that ROS may not always require active treatment. The researchers suggest that ROS should be considered in patients with brain tumors and persistent low sodium. The study highlights the importance of using water load tests to differentiate ROS from other causes of hyponatremia. No prior work had resolved whether ROS is a transient or chronic condition following tumor removal. The authors conclude that ROS may persist even after successful tumor resection. This case supports the need for further research into the pathophysiology and management of ROS.